Contact this trialFirst, we need to learn more about you.
Antibody-Drug Conjugate
Trastuzumab Deruxtecan for Cancer
Recruiting1 awardPhase 2
Kelowna, British Columbia
This trial will evaluate the safety and efficacy of trastuzumab deruxtecan, a HER2-targeting antibody drug conjugate, in patients with HER2-expressing solid tumors.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service